RxDoctor Payments DataLook up a doctor →

Dalia Fulop, MD

Diagnostic Neuroimaging · Ormond Beach, FLNPI 1578589198

Payments from drug & device makers

$210,425in general payments, 2019–2025

Across 988 payments — averaging $212.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$175K
  • Novartis$11K
  • Acadia Pharmaceuticals Inc$10K
  • Biogen$941
  • UCB, Inc.$846
  • MDD US Operations, LLC$804
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)209$175,333
Novartis86$10,687
Acadia Pharmaceuticals Inc35$10,478
Biogen54$941
UCB, Inc.31$846
MDD US Operations, LLC20$804
Argenx US, Inc.26$792
CSL Behring29$725
Pfizer43$695
Neurocrine Biosciences, Inc.23$567
Amgen(2 entities)29$566
Teva Pharmaceuticals USA, Inc.32$546
AstraZeneca22$508
Lilly USA, LLC23$487
EMD Serono, Inc.29$461
Sanofi25$456
SK Life Science, Inc.17$454
Genentech USA, Inc.22$341
Eisai Inc.12$326
Acorda Therapeutics, Inc17$321
Takeda Pharmaceuticals U.S.A., Inc.12$277
Greenwich Biosciences, Inc.16$274
Otsuka America Pharmaceutical, Inc.11$260
Mallinckrodt Hospital Products Inc.9$254
Biohaven Pharmaceutical Holding Company Ltd.13$247
Amneal Pharmaceuticals LLC12$220
Corium, LLC9$212
Jazz Pharmaceuticals Inc.9$210
Sunovion Pharmaceuticals Inc.10$195
Vanda Pharmaceuticals Inc.9$182
ANI Pharmaceuticals, Inc.7$178
Lundbeck LLC7$134
Biohaven Pharmaceuticals, Inc.6$126
Banner Life Sciences, LLC5$121
Adamas Pharmaceuticals, Inc.8$116
Avanir Pharmaceuticals, Inc.6$111
GE HealthCare5$105
Johnson & Johnson(2 entities)5$87
Scilex Pharmaceuticals Inc.4$76
Grifols USA, LLC4$67
Neurelis, Inc.4$64
Cycle Pharmaceuticals Inc4$60
Boston Scientific2$51
Mallinckrodt Enterprises LLC3$51
Kyowa Kirin, Inc.3$49
TG Therapeutics, Inc.2$45
Bristol Myers Squibb2$34
Tanabe Pharma America, Inc.2$30
Supernus Pharmaceuticals, Inc.2$28
Livanova USA, Inc.1$25
Bausch Health US, LLC1$25
Alnylam Pharmaceuticals Inc.1$22
Microtransponder, Inc.1$22
C2n Diagnostics, LLC1$21
GRT US Holding, Inc.1$18
Ipsen Biopharmaceuticals, Inc1$17
Dynasplint Systems Inc.1$16
Vertical Pharmaceuticals, LLC1$13
Arbor Pharmaceuticals, Inc.1$13
E.r. Squibb & Sons, L.L.C.1$12

How this compares

Too few diagnostic neuroimaging providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$218,634
Medicare patients
719
Services billed
1,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other diagnostic neuroimaging in Ormond Beach

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →